Given that PPP2R1A and these importins are ubiquitously expressed and that JUN, YAP, MYC, and NF-κB drive many different types of cancer (Ji et al, 2019; Taniguchi and Karin, 2018; Chen et al, 2018a; Park et al, 2020; Zanconato et al, 2019), sphingosine-like drugs should be effective across cancer classes, not just against prostate tumors. The gene discussed is JUN; the disease is prostate neoplasm.